NLS Collaboration

The report, requested by NordForsk, is titled Nordic research infrastructure collaboration – Recommendations for common Nordic activities. The report has been conducted by Professor Sven Stafström from the University of Linköping and former leader of the Swedish Research Council. In the report he investigates research infrastructure activities in the Nordic countries and presents measures that […]

A collaboration agreement between AstraZeneca, Oslo Cancer Cluster, and Oslo Science City aims to strengthen the Nordic health industry by facilitating closer collaboration between researchers, startups, and pharmaceutical companies. The focus on investment in the health industry in Norway gained momentum after Minister of Trade and Industry, Jan Christian Vestre announced at the Norway Life […]

This year’s International Women and Girls in Science Day, implemented by UNESCO and UN-Women, focused on Closing the gender gap in science: Accelerating action. Despite the progress made in recent decades, still today only one in three researchers globally is a woman, describes UNESCO. This persistent gender disparity is the result of the numerous barriers […]

The Novo Nordisk Foundation is committing up to USD 25 million to support the early-stage development of innovative tools to prevent, diagnose and treat the most dangerous drug-resistant bacterial infections. The three-year grant will go to the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit public-private partnership in this space. The partnership plays a […]

Sigrid Therapeutics has entered into an agreement with Cencora aimed at accelerating the commercialization of its SiPore technology. SiPore21 is currently undergoing SHINE clinical trials as an innovative medical device designed for sustained blood sugar and weight control. Administered orally, SiPore21 utilizes a mesoporous silica mineral to prevent digestive enzymes from breaking down carbohydrates and […]

Novo Nordisk has entered into a collaboration and license agreement with the Swiss company EraCal Therapeutics. The two companies will develop and commercialize EraCal’s oral, small molecule program. The asset is believed to target a novel mechanism of action controlling appetite and body weight to treat obesity. Milestones of up to EUR 235 million Novo […]